AASDHPPT

Across TCGA pan-cancer cohorts, AASDHPPT Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AASDHPPT data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher AASDHPPT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AASDHPPT expression acts as an unfavorable survival marker.

KIRC, BRCA, and LGG are the cancer types where AASDHPPT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.220	0.806	<.001	12	view →
BRCA	OS	Median	II,III,IV	0.121	0.565	.008	10	view →
LGG	DFS	Median	All	0.110	0.833	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AASDHPPT–KIRC (OS)

Open the KIRC breakdown →